Intervention Protocol

You have free access to this content

The use of antiarrhythmics prior to cardioversion or catheter ablation for atrial fibrillation

  1. Kelvin Ka Weng Lou1,
  2. Gregory Egan2,
  3. Aaron M Tejani3,*

Editorial Group: Cochrane Heart Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD010380


How to Cite

Lou KKW, Egan G, Tejani AM. The use of antiarrhythmics prior to cardioversion or catheter ablation for atrial fibrillation (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD010380. DOI: 10.1002/14651858.CD010380.

Author Information

  1. 1

    Lower Mainland Pharmacy Services, Department of Pharmacy, Coquitlam, BC, Canada

  2. 2

    Lower Mainland Pharmacy Services, New Westminster, BC, Canada

  3. 3

    University of British Columbia, Therapeutics Initiative, Vancouver, BC, Canada

*Aaron M Tejani, Therapeutics Initiative, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. Aaron.Tejani@fraserhealth.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

References

Additional references

Boriani 2004
  • Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004;64(24):2741–62.
Chakravarty 2012
  • Chakravarty S, Chatterjee S. Efficacy of hybrid therapy in the form of right atrial ablation and adjunctive therapy in refractory atrial fibrillation in symptomatic patients. American Journal of Therapeutics 2012;19(1):e18.
de Denus 2005
  • de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Archives of Internal Medicine 2005;165(3):258–62.
DeWilde 2006
Finta 2004
Fuster 2001
  • Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104(17):2118–50.
Go 2001
Govindan 2008
  • Govindan M, Catanchin A, Camm AJ. The place of hybrid therapies with drugs to supplement nonpharmacological therapies in atrial fibrillation. Journal of Cardiovascular Pharmacology 2008;52(3):210.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Lafuente-Lafuente 2006
  • Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Archives of Internal Medicine 2006;166(7):719.
Lefebvre 2011
  • Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Mead 2005
Noheria 2008
  • Noheria A, Kumar A, Wylie Jr JV, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Archives of Internal Medicine 2008;168(6):581.
Opolski 2004
  • Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126(2):476–86.
Oral 1999
  • Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. New England Journal of Medicine 1999;340(24):1849–54.
PRISMA 2009
  • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009; Vol. 6, issue 7:e1000097. [DOI: 10.1371/journal.pmed.1000097]
Stiell 2011
  • Stiell IG, Macle L. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Canadian Journal of Cardiology 2011;27(1):38–46.
Van Gelder 2002
  • Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. New England Journal of Medicine 2002;347(23):1834–40.
Verma 2011
  • Verma A, Macle L, Cox J, Skanes AC, for the CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Canadian Journal of Cardiology 2011;27(1):60–6.
Wilber 2010
  • Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 2010;303(4):333–40.
Wyse 2002
  • Wyse DG,  Waldo AL,  DiMarco JP,  Domanski MJ,  Rosenberg Y,  Schron EB,  et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. New England Journal of Medicine 2002;347(23):1825-33. [DOI: 10.1056/NEJMoa021328]